Praxis Precision Medicines Submits Two NDAs for Ulixacaltamide and Relutrigine, Reports Q4/FY25 Results, and Extends Cash Runway into 2028
Summary
Praxis Precision Medicines announced the submission of two New Drug Applications (NDAs) to the FDA for ulixacaltamide and relutrigine, reported Q4 and full-year 2025 financial results, and confirmed a cash runway extending into 2028.
Key Events
-
Two NDAs Submitted to FDA
Praxis submitted New Drug Applications (NDAs) for ulixacaltamide in essential tremor (ET) and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), marking a critical step towards commercialization.
-
Extended Cash Runway
The company reported $926.1 million in cash and investments as of December 31, 2025, which, combined with $621.2 million from the January 2026 public offering, is expected to fund operations into 2028.
-
Positive Pipeline Progress
Pre-launch activities for ulixacaltamide and relutrigine are accelerating, and topline results for vormatrigine (FOS) and elsunersen (SCN2A DEE) are anticipated in the first half of 2026.
-
Full-Year 2025 Financials
Praxis reported a net loss of $303.3 million for the full year 2025, with research and development expenses increasing to $267.1 million, reflecting significant investment in its pipeline.
Analysis
This 8-K filing signals a significant advancement for Praxis Precision Medicines as it transitions towards becoming a commercial-stage biopharmaceutical company. The submission of two New Drug Applications (NDAs) for ulixacaltamide in essential tremor and relutrigine in DEEs represents a major de-risking event for its pipeline, with pre-launch activities already underway. The robust cash position, bolstered by the recent public offering, provides a substantial runway into 2028, alleviating near-term financing concerns and supporting ongoing R&D and commercialization efforts. Upcoming clinical readouts for vormatrigine and elsunersen in the first half of 2026 will be key catalysts to watch, potentially adding to the company's late-stage pipeline.
At the time of this filing, PRAX was trading at $328.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $26.70 to $335.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.